Close

Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

APAC Drug Industry 2026: From Manufacturing Hub to Innovation Powerhouse

For years, APAC was mainly known for producing medicines...

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.
- Advertisement -

Bristol-Myers Squibb Company will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call athttp://investor.bms.com or by dialing in the U.S. toll free 877-201-0168 or international 647-788-4901, confirmation code: 91350399. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on July 28 through 11:59 p.m. EDT on August 11, 2016. The replay will also be available through http://investor.bms.com or by dialing in the U.S. toll free 855-859-2056 or international 404-537-3406, confirmation code: 91350399.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Contact:

Bristol-Myers Squibb Company
Media: 
Ken Dominski, 609-252-5251
ken.dominski@bms.com

or

Lisa McCormick Lavery, 609-252-7602
lisa.mccormicklavery@bms.com

or
 
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com

or

Ranya Dajani, 609-252-5330
ranya.dajani@bms.com

or

Bill Szablewski, 609-252-5894
william.szablewski@bms.com
 

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

APAC Drug Industry 2026: From Manufacturing Hub to Innovation Powerhouse

For years, APAC was mainly known for producing medicines...

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »